Associations of serum sex steroid hormone and 5α-androstane-3α, 17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride

Cancer Epidemiology Biomarkers and Prevention

Volumn 21, Issue 10, 2012, Pages 1823-1832

  Kristal, Alan R ^a,b   Till, Cathee ^a   Tangen, Catherine M ^a   Goodman, Phyllis J ^a   Neuhouser, Marian L ^a,b   Stanczyk, Frank Z ^c   Chu, Lisa W ^d   Patel, Sherfaraz K ^c   Thompson, Ian M ^e   Reichardt, Juergen K ^a,b   Hoque, Ashraful ^f   Platz, Elizabeth A ^g   Figg, William D ^d   Van Bokhoven, Adrie ^h   Lippman, Scott M ⁱ   Hsing, Ann W ^j,k  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^g JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^h UNIVERSITY OF COLORADO   (United States)

ⁱ UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^j CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

^k JAMES COOK UNIVERSITY   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTANEDIOL; ESTRADIOL; ESTRONE; FINASTERIDE; PLACEBO; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ARTICLE; CANCER PREVENTION; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; FOLLOW UP; HORMONE DETERMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TESTOSTERONE BLOOD LEVEL;

5-ALPHA REDUCTASE INHIBITORS; AGED; ANDROSTANE-3,17-DIOL; CASE-CONTROL STUDIES; FINASTERIDE; GLUCURONIDES; GONADAL STEROID HORMONES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RISK; SEX HORMONE-BINDING GLOBULIN;

EID: 84867303741     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0695     Document Type: Article

References (22)

1. Endogenous Hormones and Prostate Cancer Collaborative Group, RoddamA, Allen N, Appleby P, Key T. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100:170.
2. Rittmaster RS, Hahn RG, Ray P, Shannon JB, Wurzel R. Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Urology 2008;72:808-12.
3. Roehrborn C, Lee M, Meehan A, Waldstreicher J. Effects of finasteride on serum testosterone and body mass index in men with benign prostatic hyperplasia. Urology 2003;62:894-9. (Pubitemid 37421238)
4. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24. (Pubitemid 36859473)
5. Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Parnes HL, Lippman SM, et al. Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. J Urol 2007;177:1749-52. (Pubitemid 46560657)
6. Thompson IM, Chi C, Ankerst DP, Goodman PJ, Tangen CM, Lippman SM, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006;98:1128-33. (Pubitemid 44288787)
7. Redman MW, Tangen CM, Goodman PJ, Lucia MS, Coltman CA, Thompson IM. Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer Prev Res 2008;1:174-81.
8. Thomas LN, Douglas RC, Lazier CB, Gupta R, Norman RW, Murphy PR, et al. Levels of 5α-reductase type 1 and type 2 are increased in localized high grade compared to low grade prostate cancer. J Urol 2008;179:147-51. (Pubitemid 350216746)
9. Horton R. Testicular steroid transport, metabolism and effects. Principles and practice of endocrinology and metabolism. Philadelphia: Lippincott; 1990.
10. Thigpen A, Silver R, Guileyardo J, Casey ML, McConnell J, Russell D. Tissue distribution and ontogeny of steroid 5 alpha-reductase isozyme expression. J Clin Invest 1993;92:903-10. (Pubitemid 23262413)
11. Goodman PJ, Tangen CM, Kristal AR, Thompson IM, Platz EA, Figg WD, et al. Transition of a clinical trial into translational research: The Prostate Cancer Prevention Trial experience. Cancer Prev Res 2010;3:1523-33.
12. Narang R, Rao JN, Savjani G, Peterson J, Gentzchein E, Stanczyk FZ. Radioimmunoassay kit for the quantitative measurement of androstanediol glucuronide in unextracted serum. Proceedings of the 17th National Meeting of the Clinical Ligand Assay Society; 1991.
13. Goebelsmann U, Bernstein GS, Gale JA, Kletzky OA, Nakamura RM, Coulson AH, et al. Serum gonadotropin, testosterone, estradiol and estrone levels prior to and following bilateral vasectomy. In: Lepow I. H., Crozier R., editors. Vasectomy: immunologic and pathophysiologic effects in animals and man. New York: Academic Press; 1979. pp. 165-75.
14. Rinaldi S, Geay A, Dechaud H, Biessy C, Zeleniuch-Jacquotte A, Akhmedkhanov A, et al. Validity of free testosterone and free estradiol determinations in serum samples from postmenopausal women by theoretical calculations. Cancer Epidemiol Biomarkers Prev 2002;11:1065-71. (Pubitemid 35192658)
15. S€odergard R, B€ackstr€om T, Shanbhag V, Carstensen H. Calculation of free and bound fractions of testosterone and estradiol-17β to human plasma proteins at body temperature. J Steroid Biochem 1982;16:801-10.
16. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72. (Pubitemid 30645223)
17. Tefilli MV, Gheiler EL, Tiguert R, Sakr W, Grignon DJ, Banerjee M, et al. Should Gleason score 7 prostate cancer be considered a unique grade category? Urology 1999;53:372-7. (Pubitemid 29063329)
18. Andriole G, Bostwick D, Brawley O, Gomella L, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-202.
19. Scardino PT. The prevention of prostate cancer - the dilemma continues. N Engl J Med 2003;349:297-9. (Pubitemid 36859482)
20. Cohen Y, Liu K, Heyden N, Carides A, Anderson K, Daifotis A, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1366-74. (Pubitemid 351767189)
21. Yao S, Till C, Kristal AR, Goodman PJ, Hsing AW, Tangen CM, et al. Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study. Cancer Causes Control 2011;22:1121-31.
22. Vaughan D, Imperato-McGinley J, McConnell J, Matsumoto A, Bracken B, Roy J, et al. Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia. Urology 2002;60:1040-4. (Pubitemid 35447563)